Clinical Study

Phase II Trial Of Post-Operative Or Definitive Concurrent Radiation And Cetuximab For Locally Advanced Cutaneous Squamous Cell Carcinoma Of The Head And Neck

Posted Date: May 23, 2018

  • Investigator: Vinita Takiar
  • Specialties: Hematology/Oncology, Oncology, Radiation Oncology
  • Type of Study: Drug

Standard treatment of surgery followed by radiation can stop tumors from growing in the head and neck region in most patients. However, cancer can recur or spread. Cetuximab may delay or prevent tumor growth and is approved by the FDA for head and neck cancer. This study will determine how easily cetuximab can be added to treatment with radiation therapy. This study will also look at how well cetuximab added to radiation therapy works over time and how well this treatment is tolerated


Eligible Patients Must Have Locally Advanced Cutaneous Squamous Cell Carcinoma Of The Head And Neck.


Cutaneous, Head And Neck Cancer, Locally Advanced, Squamous Cell Carcinoma, Uchn-12-001

For More Information:

Uc Cancer Institute

  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at or (513) 245-3417.